Polysomnography (PSG) is the gold standard diagnostic tool for evaluating sleep disorders in patients with neurodegenerative diseases. For individuals with suspected corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP), PSG serves multiple critical functions: diagnosing REM sleep behavior disorder (RBD), identifying sleep-disordered breathing, characterizing sleep architecture abnormalities, and providing prognostic information regarding underlying pathology[@iranzo2024].
The integration of PSG into the diagnostic workup of atypical parkinsonism has become increasingly important as research demonstrates its utility in differentiating between tauopathies and synucleinopathies. This page provides a comprehensive guide to PSG for clinicians and patients navigating CBS/PSP evaluation.
The American Academy of Sleep Medicine (AASM) standard montage for diagnostic PSG includes[@berry2024]:
Polysomnography (PSG) is the gold standard diagnostic tool for evaluating sleep disorders in patients with neurodegenerative diseases. For individuals with suspected corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP), PSG serves multiple critical functions: diagnosing REM sleep behavior disorder (RBD), identifying sleep-disordered breathing, characterizing sleep architecture abnormalities, and providing prognostic information regarding underlying pathology[@iranzo2024].
The integration of PSG into the diagnostic workup of atypical parkinsonism has become increasingly important as research demonstrates its utility in differentiating between tauopathies and synucleinopathies. This page provides a comprehensive guide to PSG for clinicians and patients navigating CBS/PSP evaluation.
The American Academy of Sleep Medicine (AASM) standard montage for diagnostic PSG includes[@berry2024]:
| Channel Type | Electrodes/Montage | Clinical Purpose |
|--------------|-------------------|------------------|
| EEG | C3/A2, C4/A1, O1/A2, O2/A1, F3/A2, F4/A1 | Sleep staging, detect epileptiform activity |
| EOG | Left/right outer canthus referenced to contralateral mastoid | Eye movement detection for sleep staging |
| Chin EMG | Submental (mental/orbicularis oris), bilateral anterior tibialis | Muscle tone assessment for REM atonia |
| Bilateral Leg EMG | Anterior tibialis | Periodic limb movement detection |
| Respiratory | Nasal pressure transducer, oral thermistor, chest/abdominal belts | Breathing pattern analysis |
| Pulse oximetry | Continuous SpO2 | Oxygen desaturation monitoring |
| ECG | Single-lead | Cardiac rhythm monitoring |
| Body position | Position sensor | Position-related events |
For patients with suspected CBS/PSP, an extended montage is recommended[@sixeldring2024]:
| Parameter | Adult Standard |
|-----------|----------------|
| EEG, EOG | 500 Hz, 0.3-35 Hz |
| EMG | 500 Hz, 10-100 Hz |
| Respiratory | 100 Hz, 0.1-15 Hz |
| Pulse oximetry | 25 Hz |
In healthy adults, sleep comprises the following stages[@carskadon2024]:
Patients with CBS and PSP demonstrate distinctive sleep architecture patterns that differ from both healthy controls and synucleinopathies[@arnaldi2024]:
| Parameter | PSP Finding | Clinical Significance |
|-----------|-------------|----------------------|
| Total sleep time | Markedly reduced | Disease severity correlation |
| Sleep efficiency | <70% (reduced) | Frequent arousals |
| NREM N3 | Severely reduced or absent | Brainstem degeneration |
| REM sleep | Reduced (8-12% vs 20-25% normal) | Brainstem nuclei involvement |
| Sleep fragmentation | Severe | Multiple awakenings |
| Periodic limb movements | Common (60-80%) | Co-existing RLS/PLMS |
| Parameter | CBD Finding | Clinical Significance |
|-----------|-------------|----------------------|
| Total sleep time | Reduced | Motor symptoms, pain |
| Sleep efficiency | Variable (often reduced) | Fragmented sleep |
| REM sleep | Reduced | Brainstem involvement |
| Sleep apnea | Increased prevalence | Respiratory dysregulation |
| Nocturnal agitation | Common | Cortical dysfunction |
Normal PSP CBD
Sleep Efficiency >85% <70% Variable
N3 % 15-25% <5% <10%
REM % 20-25% 8-12% 10-15%
Arousal Index <15/hr >30/hr >20/hr
PLMS index <5/hr 30-60/hr 20-40/hr
The diagnosis of REM sleep without atonia (RSWA) requires quantitative analysis[@ferman2024]:
| Severity | Atonia Index | Clinical Correlate |
|----------|-------------|-------------------|
| Normal | >0.9 | Intact atonia |
| Borderline | 0.8-0.9 | Subclinical RSWA |
| Mild RBD | 0.7-0.8 | Occasional behaviors |
| Moderate RBD | 0.5-0.7 | Weekly behaviors |
| Severe RWD | <0.5 | Nightly, injurious behaviors |
The MSLT assesses daytime sleepiness and is critical for evaluating hypersomnolence in neurodegenerative patients[@littner2024]:
| Finding | Interpretation | Clinical Significance |
|---------|-----------------|---------------------|
| MSL >8 min | Normal | Appropriate alertness |
| MSL <8 min | Excessive daytime sleepiness | Medication effect, brainstem dysfunction |
| ≥2 SOREMPs | Abnormal | Narcolepsy, REM intrusion |
| 1 SOREMP | Borderline | Further evaluation needed |
Sleep-disordered breathing is common in CBS/PSP and impacts disease course[@jer2023]:
| Condition | OSA Prevalence | Risk Factors |
|-----------|---------------|--------------|
| PSP | 30-50% | Brainstem respiratory centers |
| CBS | 25-40% | Motor impairment, supine sleep |
| MSA | 60-70% | Autonomic failure |
| PD | 20-30% | Older age, longer disease |
| Event Type | Definition | Clinical Significance |
|------------|------------|----------------------|
| Obstructive apnea | ≥10 sec cessation with effort | Upper airway collapse |
| Central apnea | ≥10 sec cessation without effort | Brainstem dysfunction |
| Hypopnea | ≥30% reduction + 4% desaturation | Mixed pathology |
| RERA | Flow limitation + arousal | Upper airway resistance |
The absence of RBD in a patient with parkinsonism supports tauopathic pathology[@koga2024]:
| Finding | Tauopathy (CBS/PSP) | Synucleinopathy (PD/MSA/DLB) |
|---------|---------------------|-------------------------------|
| RBD prevalence | 0-13% | 50-90% |
| Sleep efficiency | Severely reduced | Moderately reduced |
| N3 percentage | Very low | Low-normal |
| Central apnea | Uncommon | Common in MSA |
| REM latency | Normal | Shortened |
While both are 4R-tauopathies, subtle PSG differences exist:
| Finding | CBS | PSP |
|---------|-----|-----|
| RBD | Rare (0-8%) | Rare (0-13%) |
| Sleep efficiency | Variable | Very low |
| Limb movements | Common | Very common |
| Nocturnal agitation | More common | Less common |
| Sleep architecture | Moderately abnormal | Severely abnormal |
Indications for PSG in suspected CBS/PSP[@international2024]:
| Component | Estimated Cost | Insurance Coverage |
|-----------|---------------|-------------------|
| In-lab diagnostic PSG | $1,500-3,000 | Usually covered with medical indication |
| Home sleep apnea test | $150-300 | Covered for OSA screening |
| MSLT | $800-1,500 | Usually covered |
| Split-night PSG | $2,000-3,500 | Covered if OSA diagnosed |
| Out-of-pocket (deductible) | $200-500 | Varies by plan |
Based on PSG findings, treatment modifications include:
| PSG Finding | Treatment Modification |
|-------------|----------------------|
| RBD present | Melatonin 3-12mg or clonazepam 0.25-1mg; safety modifications |
| OSA present | CPAP/BiPAP; avoid RBD positioning therapy |
| Severe PLMS | Gabapentin, pramipexole |
| Excessive daytime sleepiness | Modafinil; evaluate medications |
| Severe sleep fragmentation | Sleep hygiene; consider sedative |
For patients with RBD (regardless of PSG confirmation)[@st2024]:
The following diagram shows the key molecular relationships involving Polysomnography (PSG) - Comprehensive Sleep Study Guide for Atypical Parkinsonism discovered through SciDEX knowledge graph analysis: